Obinutuzumab versus rituximab-based chemotherapy in high-tumor burden indolent B-cell lymphoma: a real-world comparative study
BackgroundPatients with previously untreated follicular lymphoma (FL) or marginal zone lymphoma (MZL) with high-tumor burden represent a subset with unfavorable prognosis. However, the efficacy of obinutuzumab in this specific high-risk population rema…